|
Feb 15
|
Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations
|
|
Feb 14
|
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
|
|
Feb 14
|
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...
|
|
Feb 14
|
Q4 2024 Blueprint Medicines Corp Earnings Call
|
|
Feb 13
|
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 13
|
Blueprint Medicines: Q4 Earnings Snapshot
|
|
Feb 13
|
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
|
|
Feb 11
|
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
|
|
Jul 29
|
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
|
|
Jul 25
|
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Mar 29
|
Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?
|
|
Mar 28
|
Insiders Are Dumping These 10 Healthcare Stocks
|
|
Dec 18
|
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 14
|
Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)
|
|
Dec 12
|
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
|
|
Dec 11
|
Blueprint Medicines' (NASDAQ:BPMC) investors will be pleased with their respectable 63% return over the last year
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 9
|
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
|
|
Dec 7
|
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
|
|
Dec 6
|
Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?
|